Search Result

Results for "

Parkinson's disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Acyltransferase (2) Adenosine Receptor (4) Adenylate Cyclase (3) Adrenergic Receptor (2) Akt (4) Amyloid-β (2) Antibiotic (3) AP-1 (1) Apoptosis (22) Arrestin (2) Aryl Hydrocarbon Receptor (7) Autophagy (5) Bacterial (4) Bcl-2 Family (1) Bcr-Abl (7) Biochemical Assay Reagents (3) c-Met/HGFR (1) Calcium Channel (1) Cannabinoid Receptor (1) Carbonic Anhydrase (5) Caspase (11) CCR (1) Cholinesterase (ChE) (16) COMT (8) COX (3) Cytochrome P450 (1) Dengue Virus (1) Deubiquitinase (1) DNA/RNA Synthesis (2) Dopamine Receptor (30) Drug Metabolite (6) Dynamin (1) DYRK (2) EAAT (1) Endogenous Metabolite (7) ERK (3) Estrogen Receptor/ERR (1) FAK (1) Filovirus (3) Fluorescent Dye (1) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (2) GDNF Receptor (1) Glucocorticoid Receptor (1) Glycosidase (3) GlyT (3) GPR55 (2) GPR6 (1) GSK-3 (2) HBV (1) Heme Oxygenase (HO) (4) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (3) Histone Demethylase (2) IAP (1) iGluR (5) Imidazoline Receptor (2) Integrin (1) Interleukin Related (8) Isotope-Labeled Compounds (16) JAK (1) JNK (2) Keap1-Nrf2 (10) LRRK2 (19) mAChR (6) MAGL (1) MAP4K (1) MDM-2/p53 (1) MEK (1) mGluR (7) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) Mitophagy (2) Mixed Lineage Kinase (4) MMP (2) MNK (1) Monoamine Oxidase (31) nAChR (2) NAMPT (1) Necroptosis (4) Neurotensin Receptor (1) NF-κB (2) NO Synthase (6) NOD-like Receptor (NLR) (5) Nuclear Hormone Receptor 4A/NR4A (4) OAT (2) OGA (1) Opioid Receptor (2) P-glycoprotein (11) p38 MAPK (2) Parasite (3) PARP (2) PDK-1 (2) PGE synthase (2) Phosphodiesterase (PDE) (1) PI3K (1) PINK1/Parkin (1) PKC (3) Potassium Channel (3) PROTACs (6) Pyroptosis (4) Radionuclide-Drug Conjugates (RDCs) (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (8) Reference Standards (22) RET (1) RIP kinase (1) ROCK (1) SARS-CoV (3) Sigma Receptor (1) Sirtuin (2) SOD (1) Sodium Channel (1) Src (1) STAT (1) Stearoyl-CoA Desaturase (SCD) (1) Survivin (1) Tau Protein (2) TNF Receptor (5) TNK1 (2) Toll-like Receptor (TLR) (2) Trace Amine-associated Receptor (TAAR) (1) Tyrosine Hydroxylase (2) ULK (2) VEGFR (1) Wnt (1) α-synuclein (25) β-catenin (2) β-glucuronidase (1)
By Research Areas:	Cancer (43) Cardiovascular Disease (14) Endocrinology (6) Infection (11) Inflammation/Immunology (31) Metabolic Disease (21) Neurological Disease (249)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Guanine Nucleotide (1) Nucleotide Analogs (1) Phospholipids (1)

260

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15608

MPTP hydrochloride 85+ Cited Publications	Dopamine Receptor Apoptosis	Neurological Disease Inflammation/Immunology
MPTP hydrochloride is a brain penetrant dopaminergic neurotoxin. MPTP hydrochloride can be used to induce Parkinson’s Disease model. MPTP hydrochloride, a precusor of MPP ⁺, induces apoptosis . MPTP hydrochloride has been verified by MCE with professional biological experiments.

HY-100411

MLi-2 10+ Cited Publications	LRRK2	Neurological Disease
MLi-2, a chemical probe, is an orally active and highly selective LRRK2 inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .

HY-W114750

MPTP 85+ Cited Publications	Dopamine Receptor Apoptosis	Neurological Disease Inflammation/Immunology
MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a brain penetrant dopamine neurotoxin. MPTP can be used to induce Parkinson’s Disease model. MPTP, a precusor of MPP ⁺, induces apoptosis .

HY-N7560

Safranal Maximum Cited Publications 6 Publications Verification	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research .

HY-147976

Glucocerebrosidase-IN-1	Glycosidase	Neurological Disease Metabolic Disease
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-162666

TMEM175 modulator 1	Potassium Channel	Neurological Disease
TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia .

HY-N5077

Sinapine 2 Publications Verification	Cholinesterase (ChE) P-glycoprotein	Neurological Disease Inflammation/Immunology Cancer
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N0450

Sinapine thiocyanate 2 Publications Verification	P-glycoprotein Cholinesterase (ChE)	Cancer
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-124876

SynuClean-D 1 Publications Verification SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-175748

MK-7337	Radionuclide-Drug Conjugates (RDCs) α-synuclein	Neurological Disease
MK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with ¹¹C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .

HY-14561A

Idazoxan hydrochloride RX 781094 hydrochloride	Adrenergic Receptor Imidazoline Receptor	Neurological Disease Endocrinology
Idazoxan hydrochloride (RX 781094 hydrochloride) is an α₂-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .

HY-109131

Foscarbidopa ABBV-951; Carbidopa 4′-monophosphate	Aryl Hydrocarbon Receptor Drug Metabolite	Neurological Disease
Foscarbidopa (ABBV-951; Carbidopa 4′-monophosphate) is an inhibitory prodrug targeting peripheral aromatic L-amino acid decarboxylase. Foscarbidopa is hydrolyzed into Carbidopa (HY-B0311) by phosphatases in vivo to suppress peripheral metabolism of levodopa and elevate brain delivery of levodopa. Foscarbidopa can be used for the research of Parkinson’s disease and advanced Parkinson’s disease .

HY-125515

Tetrahydroharmine Leptaflorine	Monoamine Oxidase	Neurological Disease
Tetrahydroharmine (Leptaflorine) is a selective reversible monoamine oxidase A (MAO-A) inhibitor with an IC₅₀ of 74 nM. Tetrahydroharmine can be used for the research of parkinson’s disease .

HY-B1607

Chlorphenoxamine 1 Publications Verification	Histamine Receptor SARS-CoV Filovirus Parasite	Infection Neurological Disease Inflammation/Immunology
Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with *IC₅₀s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases* and Parkinson’s disease .

HY-156586

Egalognastat ASN90	OGA Tau Protein	Neurological Disease
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC₅₀ value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .

HY-107660

SIRT2-IN-8	Sirtuin	Neurological Disease
SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-125558

PT150 ORG-34517	Glucocorticoid Receptor	Neurological Disease
PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .

HY-W062697

HTL14242 1 Publications Verification HTL0014242	mGluR	Neurological Disease
HTL14242 (HTL0014242) is an advanced and orally active mGlu5 NAM with a pK_i and a pIC₅₀ of 9.3 and 9.2, respectively . HTL14242 can be used for the research of parkinson’s disease .

HY-176200

VU6008055 AF98943	mAChR	Neurological Disease
VU6008055 (AF98943) is a brain-penetrant, orally active and selective muscarinic acetylcholine receptor subtype 4 (mAChR4) activator with human EC₅₀ values of 73.4 nM. VU6008055 potentiates mAChR4 receptor activity in the presence of acetylcholine, and exhibits no activity at mAChR1, mAChR3, or mAChR5. VU6008055 can be used for the research of schizophrenia, parkinson’s disease, alzheimer’s disease .

HY-105545

Dexetimide (+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide	mAChR	Neurological Disease
Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease .

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .

HY-150058

Bocconoline	Others	Neurological Disease
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-163830

Pegasus DAD9	Dopamine Receptor	Neurological Disease
Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease .

HY-112555

PDE7-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC₅₀ value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease .

HY-P2777

Ceruloplasmin	Biochemical Assay Reagents	Neurological Disease Metabolic Disease Inflammation/Immunology
Ceruloplasmin is a copper-containing multifunctional ferrous oxidase glycoprotein. Ceruloplasmin specifically oxidizes Fe ²⁺ to Fe ³⁺, promoting the binding of Fe ³⁺ to transferrin. Ceruloplasmin can bind to copper ions to prevent the toxicity of free copper to cells. Ceruloplasmin can be used for the research of inflammation, metabolic and neurological disease such as Parkinson’s disease .

HY-119910

(E)-Aminoquinol XIB4035	GDNF Receptor	Neurological Disease
(E)-Aminoquinol (XIB4035) is a GFRα-1 agonist. (E)-Aminoquinol has mimic neurotrophic effects of GDNF, and induces Ret autophosphorylation in Neuro-2A cells. (E)-Aminoquinol can be used for research of Parkinson’s disease .

HY-172967

SARM1-IN-5	Toll-like Receptor (TLR)	Neurological Disease
SARM1-IN-5 (compound 1-23-a) is a SARM1 inhibitor. SARM1-IN-5 can be used in the study of axonal degeneration related diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-105003

ST 1535	Adenosine Receptor	Neurological Disease
ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease .

HY-124729A

(Rac)-BL-918	ULK Autophagy	Neurological Disease
(Rac)-BL-918 is the racemate of BL-918. BL-918 is a potent activator of UNC-51-like kinase 1 (ULK1), inducing cytoprotective autophagy for Parkinson’s disease treatment .

HY-134661

(S)-CVN424	GPR6	Neurological Disease
(S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease .

HY-115038

ELN484228	α-synuclein	Neurological Disease
ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.

HY-147976A

Glucocerebrosidase-IN-1 hydrochloride	Glycosidase	Neurological Disease
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 hydrochloride can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-178796

PROTAC LRRK2 Degrader-4	PROTACs LRRK2	Neurological Disease Inflammation/Immunology
PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC₅₀ of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation .

HY-178797

PROTAC LRRK2 Degrader-3	PROTACs LRRK2	Neurological Disease Inflammation/Immunology
PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC₅₀ of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation .

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

HY-151388

hMAO-B/MB-COMT-IN-1	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .

HY-114549

(R)-SCH-23982 hydrochloride	Dopamine Receptor	Neurological Disease
(R)-SCH-23982 hydrochloride is the R-enantiomer of SCH-23982 hydrochloride. SCH-23982 hydrochloride is a selective dopamine D1 receptor antagonist. (R)-SCH-23982 hydrochloride is promising for research of central nervous system disorders such as schizophrenia, Parkinson’s disease .

HY-124751

YTX-465	Stearoyl-CoA Desaturase (SCD)	Neurological Disease
YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with *IC₅₀s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s* disease and other synucleinopathies .

HY-152671

hMAO-B-IN-4	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC₅₀ value and a K_i value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC₅₀ value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-14555

S 33138	Dopamine Receptor	Neurological Disease
S33138 is a D3 receptor antagonist. S33138 inhibits addiction in animal models of addiction. S33138 reduces cognitive impairment in rodent and primate models of schizophrenia and Parkinson's disease. S33138 can be used in research on neurological disorders such as schizophrenia and Parkinson's disease .

HY-N10283

Neoechinulin C	Endogenous Metabolite	Neurological Disease
Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-N16524

Alpinin A	α-synuclein	Neurological Disease
Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease .

HY-N5077R

Sinapine (Standard)	Reference Standards Cholinesterase (ChE) P-glycoprotein	Neurological Disease Inflammation/Immunology Cancer
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-16468A

Squalamine phosphate ENT 01; MSI-1256 phosphate	α-synuclein	Neurological Disease
Squalamine phosphate (Compound ENT-01) is an orally active neuroprotective agent. Squalamine phosphate can displace α-Syn that is bound electrostatically to nerve cell membranes and prevent aggregation of α-Syn. Squalamine phosphate can be used for the research of neurological disease, such as Parkinson’s disease .

HY-118238

Remeglurant MRZ-8456	mGluR	Neurological Disease
Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC₅₀ of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD) .

HY-144074

LRRK2-IN-4	LRRK2	Neurological Disease
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC₅₀ of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .

HY-176213

JNK2/3-IN-1	JNK	Neurological Disease
JNK2/3-IN-1 (Compound 56d) is an irreversible covalent inhibitor of c-Jun N-terminal kinases 2/3 (JNK2/3) with IC₅₀ values of 830 and 1909 nM, respectively. JNK2/3-IN-1 is promising for research of neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s) and fibrotic disorders .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

2,085 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 2,085 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L028

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L086

Neurodegenerative Disease-related Compound Library

3,545 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,545 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L070

Neuroprotective Compound Library

1,748 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1,748 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P10409

SHLP2 Small humanin-like peptide 2	Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16468

Squalamine 1 Publications Verification MSI-1256; ENT-01 free acid	Infection Triterpenes Animals Classification of Application Fields Terpenoids Marine natural products Other marine organisms Disease Research Fields Cancer	Bacterial HBV FAK Dengue Virus
Squalamine (MSI-1256) is an aminosterol compound with broad-spectrum antiviral activity. Squalamine makes cells less conducive to certain viral replication by altering the electrostatic interactions in the inner membrane of host cells. Squalamine also has antibacterial and antitumor activities. Squalamine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria, fungi and protozoa. Squalamine inhibits tumor-related angiogenesis and the growth of human breast cancer cells. Squalamine restores the function of enteric nervous system in Parkinson ^,s disease mouse models .

HY-N7560

Safranal Maximum Cited Publications 6 Publications Verification	Ketones, Aldehydes, Acids Lridaceae Plants Crocus sativus L. Source Classification	Keap1-Nrf2
Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research .

HY-113202

Stearoylcarnitine 1 Publications Verification	Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite PKC GlyT
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

HY-N5077

Sinapine 2 Publications Verification	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Cruciferae Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Cholinesterase (ChE) P-glycoprotein
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N0450

Sinapine thiocyanate 2 Publications Verification	Alkaloids Monophenols Classification of Application Fields Other Alkaloids Cruciferae Phenols Plants Disease Research Fields Source Classification Cancer	P-glycoprotein Cholinesterase (ChE)
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-118020A

Loliolide Loliolid; Digiprolactone	Natural Products Classification of Application Fields Metabolic Disease Plants Compositae Millettia usaramensis Taub. Disease Research Fields Source Classification	Endogenous Metabolite Caspase PI3K Apoptosis Akt Sirtuin Reactive Oxygen Species (ROS) NF-κB MMP
Loliolide (Loliolid) is a β-carotene metabolite. Loliolide reduces caspase 3, 8, 9 expression, enhances PI3K, AKT, SIRT1, inhibits ROS, apoptosis, and blocks NF-κB p65 nuclear translocation. Loliolide protects mitochondria, reduces oxidative stress, and increases cell viability in neuroblastoma cells. Loliolide can be used for the research of UV-induced skin damage and Parkinson’s disease .

HY-B0927

Hydrastine (-)-β-Hydrastine; (1R,9S)-β-Hydrastine	Alkaloids Piperidine Alkaloids Classification of Application Fields Ranunculaceae Other Diseases Plants Disease Research Fields	Tyrosine Hydroxylase Dopamine Receptor OAT
Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC₅₀=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC₅₀=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .

HY-N1970

5,7-Dihydroxychromone 2 Publications Verification	Structural Classification Flavonoids other families Phenols Polyphenols Plants Isoflavones Source Classification	Keap1-Nrf2 Caspase PARP Fungal
5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-125515

Tetrahydroharmine Leptaflorine	Structural Classification Alkaloids Banisteriopsis caapi (Spruce ex Griseb.) Morton Malpighiaceae Plants Indole Alkaloids Source Classification	Monoamine Oxidase
Tetrahydroharmine (Leptaflorine) is a selective reversible monoamine oxidase A (MAO-A) inhibitor with an IC₅₀ of 74 nM. Tetrahydroharmine can be used for the research of parkinson’s disease .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Neurological Disease Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis .

HY-W018324

5-Hydroxymethylcytosine 5hmC	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

HY-112817

8-Oxo-dGTP 8-Oxo-Deoxyguanosine triphosphate	Microorganisms Source Classification	Apoptosis
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .

HY-150058

Bocconoline	Alkaloids Bocconia pearcei Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Others
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-N12302

Scotanamine D N1-Dihydrocaffeoyl, N10-caffeoyl spermidine	Structural Classification Phenols Polyphenols Lycium ruthenicum Murray Solanaceae Plants Source Classification	mAChR
Scotanamine D (N1-Dihydrocaffeoyl, N10-caffeoyl spermidine) is a spermidine alkaloid. It can be isolated from S. tangutica. Scotanamine D potently and selectively inhibits the activity of the M1 muscarinic acetylcholine receptor, with an IC₅₀ of 32 nM. It can be used in studies related to Parkinson's disease .

HY-N10283

Neoechinulin C	Alkaloids Microorganisms Indole Alkaloids Source Classification	Endogenous Metabolite
Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model .

HY-N16524

Alpinin A	Structural Classification Phenols Polyphenols Alpinia officinarum Hance Plants Source Classification Zingiberaceae	α-synuclein
Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease .

HY-N5077R

Sinapine (Standard)	Alkaloids Structural Classification Monophenols Other Alkaloids Cruciferae Phenols Plants Source Classification	Reference Standards Cholinesterase (ChE) P-glycoprotein
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N16649

Clausenalansine B	Structural Classification Alkaloids Clausena lansium (Lour.) Skeels Rutaceae Carbazole Alkaloids Plants Source Classification	Others
Clausenalansine B (Compound 2) is a carbazole alkaloid found in the fruits of Clausena lansium. Clausenalansine B exhibits potent neuroprotective effects. Clausenalansine B prevents SH-SY5Y cells death from 6-OHDA (HY-B1081A) with an EC₅₀ of 5.82 μM. Clausenalansine B can be used for the research of neurological disease, such as Parkinson’s disease .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Structural Classification Flavonoids other families Phenols Polyphenols Plants Isoflavones Source Classification	Reference Standards Keap1-Nrf2 Caspase PARP Fungal
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone (HY-N1970). This product is intended for research and analytical applications. 5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-W230975

(E/Z)-Piperine (E/Z)-Bioperine; (E/Z)-1-Piperoylpiperidine	Alkaloids Piperidine Alkaloids Piperaceae Plants Piper nigrum Linn. Source Classification	Cytochrome P450 P-glycoprotein
(E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease .

HY-N5077B

Sinapine hydroxide	Alkaloids Monophenols other families Classification of Application Fields Neurological Disease Phenols Plants Disease Research Fields Inflammation/Immunology Source Classification	Cholinesterase (ChE) P-glycoprotein
Sinapine hydroxide is an alkaloid isolated from seeds of the cruciferous species. Sinapine hydroxide exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine hydroxide is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N10365

6-(1-Hydroxyethyl)-5,6-dihydrochelerythrine	Alkaloids Macleaya cordata (Willd.) R. Br. Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Autophagy
6-(1-Hydroxyethyl)-5,6-dihydrochelerythrine, a alkaloid, significantly perturbates the features of cellular organelles including early endosomes, mitochondria and autophagosomes (Parkinson’s Disease patient-derived olfactory cells) .

HY-N12657

Retinestatin	Natural Products Microorganisms Source Classification	Others
Retinestatin, a new polyol polyketide, can protect SH-SY5Y dopaminergic cells from MPP ⁺ (HY-W008719)-induced cytotoxicity. Retinestatin shows neuroprotective effects in an in vitro model of Parkinson’s disease .

HY-N0450R

Sinapine thiocyanate (Standard)	Alkaloids Structural Classification Monophenols Other Alkaloids Cruciferae Phenols Plants Source Classification	Reference Standards P-glycoprotein Cholinesterase (ChE)
Sinapine (thiocyanate) (Standard) is the analytical standard of Sinapine (thiocyanate). This product is intended for research and analytical applications. Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease .

HY-N2998R

Ganoderenic acid A (Standard)	Triterpenes Structural Classification Human Gut Microbiota Metabolites Microorganisms other families Terpenoids Plants Endogenous metabolite Source Classification	Reference Standards β-glucuronidase
Carbidopa (monohydrate) (Standard) is the analytical standard of Carbidopa (monohydrate). This product is intended for research and analytical applications. Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth .

HY-B0927R

Hydrastine (Standard) (-)-β-Hydrastine (Standard); (1R,9S)-β-Hydrastine (Standard)	Structural Classification Alkaloids Piperidine Alkaloids Ranunculaceae Plants	Reference Standards Tyrosine Hydroxylase Dopamine Receptor OAT
Hydrastine (Standard) is the analytical standard of Hydrastine (HY-B0927). This product is intended for research and analytical applications. Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC₅₀=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC₅₀=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .

HY-186179

N-Methylnorsalsolinol	Structural Classification Monophenols Phenols Endogenous metabolite Source Classification	Endogenous Metabolite
N-Methylnorsalsolinol is an endogenous MPTP (HY-15608)-like compound. N-Methylnorsalsolinol shows neurotoxicity in vitro. N-Methylnorsalsolinol can be used for the study of Parkinson’s disease .

HY-N17990

Sexangularetin 3-sophoroside	Structural Classification Flavonoids Flavones Rosa hugonis Hemsl. Rosaceae Plants Source Classification	PDK-1 Akt GSK-3 Reactive Oxygen Species (ROS)
Sexangularetin 3-sophoroside is a PDK1 and Akt phosphorylation activator with neuroprotective properties. Sexangularetin 3-sophoroside restores phosphorylated GSK-3β protein levels. Sexangularetin 3-sophoroside acts as a ROS inhibitor and regulates mRNA expression of superoxide dismutase 1 and catalase. Sexangularetin 3-sophoroside can be used for the research of Parkinson’s disease .

Cat. No.	Product Name	Chemical Structure

HY-14280S

Entacapone-d10

Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 μM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders .

HY-G0017S

N-Desmethyl imatinib-d8

N-Desmethyl imatinib-d₈ is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .

HY-B0311AS

Carbidopa-d3 monohydrate
Carbidopa-d₃ (monohydrate) is the deuterium labeled Carbidopa monohydrate. Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth .

HY-100573S

Necrosulfonamide-d4

Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-B1018AS

Phenelzine-d5 sulfate

Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .

HY-113202S

Stearoyl-L-carnitine-d3

Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

HY-B0124S2

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-113202S1

Stearoyl-L-carnitine-d9 chloride

Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

HY-B0623AS1

Ropinirole-d7 hydrochloride

Ropinirole-d₇ hydrochloride is the deuterium labeled Ropinirole hydrochloride . Ropinirole (SKF 101468) hydrochloride is an orally active, potent D3/D2 receptor agonist with a K_i of 29 nM for D2 receptor. Ropinirole hydrochloride has pEC₅₀s of 7.4, 8.4 and 6.8 for hD2, hD3 and hD4 receptors, respectively. Ropinirole hydrochloride has no affinity for the D1 receptors. Ropinirole hydrochloride has the potential for Parkinson's disease .

HY-B0623AS2

Ropinirole-d3 hydrochloride

Ropinirole-d₃ hydrochloride is the deuterium labeled Ropinirole hydrochloride . Ropinirole (SKF 101468) hydrochloride is an orally active, potent D3/D2 receptor agonist with a K_i of 29 nM for D2 receptor. Ropinirole hydrochloride has pEC₅₀s of 7.4, 8.4 and 6.8 for hD2, hD3 and hD4 receptors, respectively. Ropinirole hydrochloride has no affinity for the D1 receptors. Ropinirole hydrochloride has the potential for Parkinson's disease .

HY-17368S1

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-B0623AS

Ropinirole-d4 hydrochloride

Ropinirole-d₄ (SKF 101468-d₄) hydrochloride is the deuterium labeled Ropinirole hydrochloride. Ropinirole hydrochloride is a potent D3/D2 receptor agonist with a K_iof 29 nM for D2 receptor. Ropinirole hydrochloride has pEC₅₀s of 7.4, 8.4 and 6.8 for hD2, hD3 and hD4 receptors, respectively. Ropinirole hydrochloride has no affinity for the D1 receptors. Ropinirole hydrochloride has the potential for Parkinson's disease .

HY-B0623AS3

Ropinirole-d14 hydrochloride

Ropinirole-d₁₄ hydrochloride is deuterated labeled Ropinirole hydrochloride (HY-B0623A). Ropinirole (SKF 101468) hydrochloride is an orally active, potent D₃/D₂ receptor agonist with a K_i of 29 nM for D₂ receptor. Ropinirole hydrochloride has pEC₅₀s of 7.4, 8.4 and 6.8 for hD₂, hD₃ and hD₄ receptors, respectively. Ropinirole hydrochloride has no affinity for the D₁ receptors. Ropinirole hydrochloride has the potential for Parkinson's disease .

HY-W018324S

5-Hydroxymethylcytosine-13C,d2

5-Hydroxymethylcytosine- ¹³C,d₂ is the ¹³C and deuterium labeled 5-Hydroxymethylcytosine (HY-W018324). 5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

HY-G0017S1

N-Desmethyl imatinib-d4

N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .

HY-W654335

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-B0623S1

Ropinirole-d3

Ropinirole-d₃ (SKF 101468-d₃) is deuterium labeled Ropinirole. Ropinirole (SKF 101468) is an orally active, potent D₃/D₂ receptor agonist with a K_i of 29 nM for D₂ receptor. Ropinirole has pEC₅₀s of 7.4, 8.4 and 6.8 for hD₂, hD₃ and hD₄ receptors, respectively. Ropinirole has no affinity for the D₁ receptors. Ropinirole has the potential for Parkinson's disease .

HY-B0124S3

Zonisamide-15N,d4

Zonisamide- ¹⁵N,d₄ is the ¹⁵N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-W654336

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Cat. No.	Product Name		Classification

HY-D2871

DAyne		Alkynes
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

Cat. No.	Product Name		Classification

HY-157700

Hexadecenyl-2-hydroxy-sn-glycero-3-PC C16(Plasm) LPC; Lysophosphatidylcholine 16:0p/0:0		Phospholipids
Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research .

HY-112817A

8-Oxo-dGTP trisodium solution (100 mM) 8-Oxo-Deoxyguanosine triphosphate trisodium		Nucleotide Analogs Guanine Nucleotide
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks